Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.43 |
| ▸ | GPR6 | P46095 | 10/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.39 |
| ▸ | PDE9A | O76083 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20147415 | 0.88 | SLC6A4 (0.53) | SLC6A4GRIN1GRIN2BGPR6CYP2D6 | |
| SCHEMBL20158435 | 0.85 | HSD11B1 (0.47) | SLC6A4GRIN1GRIN2BPDE9A | |
| SCHEMBL20068828 | 0.80 | SLC6A4 (0.52) | SLC6A4GRIN1GRIN2BGPR6CYP2D6 | |
| SCHEMBL20205883 | 0.78 | PDE9A (0.41) | GRIN1GRIN2BPDE9A | |
| SCHEMBL20158870 | 0.74 | SLC6A2 (0.40) | SLC6A4PDE9A | |
| SCHEMBL24188508 | 0.73 | SLC6A4 (0.51) | SLC6A4PDE9A | |
| SCHEMBL29555 | 0.73 | GRIN1 (0.43) | SLC6A4GRIN1GRIN2BGPR6CYP2D6 | |
| SCHEMBL20070185 | 0.72 | HSD11B1 (0.48) | SLC6A4GRIN1GRIN2B | |
| SCHEMBL19262515 | 0.71 | GPR6 (0.51) | GPR6CYP2D6 | |
| SCHEMBL2299176 | 0.69 | GRIN1 (0.40) | GRIN1GRIN2BGPR6CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180148445-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180148445-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | SLC6A4 3586/4885GRIN1 773/4885GRIN2B 1206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.